Patents by Inventor David M. Briscoe

David M. Briscoe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED SEMAPHORINS AND USES THEREOF
    Publication number: 20240092845
    Abstract: Provided herein are methods and compositions comprising or using mutant semaphorin polypeptides.
    Type: Application
    Filed: March 10, 2023
    Publication date: March 21, 2024
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. BRISCOE, Diane BIELENBERG, Johannes WEDEL
  • METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
    Publication number: 20230256053
    Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
    Type: Application
    Filed: April 6, 2023
    Publication date: August 17, 2023
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. BRISCOE, Michael KLAGSBRUN, Sarah BRUNEAU, Nora KOCHUPURAKKAL, Hironao NAKAYAMA
  • ENGINEERED SEMAPHORINS AND USES THEREOF
    Publication number: 20210324024
    Abstract: Provided herein are methods and compositions comprising or using mutant semaphorin polypeptides.
    Type: Application
    Filed: August 27, 2019
    Publication date: October 21, 2021
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. BRISCOE, Diane R. BIELENBERG, Johannes WEDEL
  • METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
    Publication number: 20190388505
    Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
    Type: Application
    Filed: September 5, 2019
    Publication date: December 26, 2019
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. BRISCOE, Michael KLAGSBRUN, Sarah BRUNEAU, Nora KOCHUPURAKKAL, Hironao NAKAYAMA
  • Methods and compositions for immunomodulation
    Patent number: 10456445
    Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: October 29, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. Briscoe, Michael Klagsbrun, Sarah Bruneau, Nora Kochupurakkal, Hironao Nakayama
  • METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
    Publication number: 20170100456
    Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
    Type: Application
    Filed: June 1, 2015
    Publication date: April 13, 2017
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: David M. BRISCOE, Michael KLAGSBRUN, Sarah BRUNEAU, Nora KOCHUPURAKKAL, Hironao NAKAYAMA
  • NON-INVASIVE METHODS FOR DIAGNOSING CHRONIC ORGAN TRANSPLANT REJECTION
    Publication number: 20140199781
    Abstract: Presented herein are methods of diagnosing or assessing an individual at increased risk of developing chronic rejection, or chronic allograft vasculopathy, based on analysis the individual's biomarker profile.
    Type: Application
    Filed: March 8, 2012
    Publication date: July 17, 2014
    Applicants: Beth Israel Deaconess Medical Center, Inc., Children's Medical Center Corporation
    Inventors: David M. Briscoe, Kevin P. Daly, Ananth Karumanchi, Michael Seifert
  • Treatment of allograft rejection with anti-angiogenic agents
    Publication number: 20010014663
    Abstract: The invention relates a method of inhibiting allograft rejection in a subject with an organ transplant. The method comprises administering an effective amount of one or more anti-angiogenic agents to a subject alone or in combination with one or more immunosuppressive agents. The invention provides new and improved methods of inhibiting allograft rejection.
    Type: Application
    Filed: January 17, 2001
    Publication date: August 16, 2001
    Inventors: David M. Briscoe, Karen Moulton, Mohamed H. Sayegh
  • Treatment of chronic allograft rejection with anti-angiogenic agents
    Patent number: 6218361
    Abstract: The invention relates a method of inhibiting chronic allograft rejection in a subject with an organ transplant. The method comprises administering an effective amount of one or more anti-angiogenic agents to a subject alone or in combination with one or more immunosuppressive agents. The invention provides new and improved methods of inhibiting allograft rejection.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: April 17, 2001
    Assignee: Children's Medical Center Corporation
    Inventors: David M. Briscoe, Karen Moulton, Mohamed H. Sayegh